What monoclonal antibody is used to prevent RSV in infants?

Palivizumab is a monoclonal antibody specifically designed for the prevention of respiratory syncytial virus (RSV) infection in high-risk infants. It works by providing passive immunity, meaning it supplies pre-formed antibodies to protect vulnerable infants during RSV season. This is particularly important because RSV can cause serious respiratory illness in young children, especially those who are premature or have underlying health issues.

The other options mentioned are not monoclonal antibodies or do not target RSV specifically. Ribavirin is an antiviral medication but is not used for prevention of RSV and is not a monoclonal antibody. Immunoglobulin refers to a broader category of antibody preparations rather than a specific monoclonal antibody used for RSV. Valacyclovir is an antiviral drug used primarily for herpes virus infections and lacks relevance to RSV prevention. Therefore, Palivizumab stands out as the effective and targeted strategy for preventing RSV in infants.